Is androgen substitution necessary in hypogonadal patients when they are treated with chemotherapy for malignant diseases?
- 1 January 1989
- journal article
- research article
- Published by Wiley in Medical and Pediatric Oncology
- Vol. 17 (3) , 222-226
- https://doi.org/10.1002/mpo.2950170310
Abstract
A patient with hypogonadotropic hypogonadism owing to endogenous gonadotropin releasing hormone deficiency, who developed Hodgkin's disease is described. Chemotherapy administration caused prolonged and life‐threatening myelosuppression; androgen substitution seemed to reverse bone marrow function and to maintain normal peripheral blood counts. Whether or not androgens are a necessary substitution in hypogonadal patients suffering from cancer and undergoing chemotherapy is discussed.Keywords
This publication has 16 references indexed in Scilit:
- Deca-Durabolin® and cytotoxic drugsActa Endocrinologica, 1985
- The Effect of Androstanes on Granulopoiesis in Vitro and in VivoBritish Journal of Haematology, 1977
- Anabolic Steroids and Bone Marrow Toxicity During Therapy with MethotrexateBritish Journal of Cancer, 1972
- Leucopoietic Properties of Four Different Androgenic Hormones in Irradiated RatsScandinavian Journal of Haematology, 1971
- The Effect of Testosterone, Adrenal Steroids and Prolactin on ErythropoiesisActa Haematologica, 1967
- Androgens and ErythropoiesisArchives of internal medicine (1960), 1961
- ANDROGEN THERAPY FOR REFRACTORY ANEMIA: REPORT OF A CASE ASSOCIATED WITH THYMOMAAnnals of Internal Medicine, 1960
- The Treatment of Chronic LeukemiaMedical Clinics of North America, 1954
- EFFECTS OF HYPOPHYSECTOMY, CASTRATION, AND TESTOSTERONE PROPIONATE ON HEMOPOIESIS IN THE ADULT MALE RAT1Endocrinology, 1946
- Effect of Castration and Sex Hormones on Blood of the RatExperimental Biology and Medicine, 1941